Oğuz Kaan Köksal

Dr. Oğuz Kaan Köksal

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2025 in Journal of the Turkish-German Gynecological Association
Verified
Journal Article
Open access
PDF file
CHCandost Hanedan
Candost Hanedan
HÖHande Nur Nur Öncü
Hande Nur Nur Öncü
NÖNeslihan öztürk
Neslihan öztürk
GEGökçen Ege
Gökçen Ege
OKOğuz Kaan Köksal
Oğuz Kaan Köksal
VKVakkas Korkmaz
Vakkas Korkmaz
Feasibility of vNOTES hysterectomy in patients with enlarged uteri: a single-center experience - Journal of the Turkish-German Gynecological Association

22 July 2025 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
NÖNeslihan öztürk
Neslihan öztürk
BEBurak Ersak
Burak Ersak
HÖHande Nur Nur Öncü
Hande Nur Nur Öncü
GEGökçen Ege
Gökçen Ege
BYBaran Yesil
Baran Yesil
VKVakkas Korkmaz
Vakkas Korkmaz

28 April 2026 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
OKOğuz Kaan Köksal
Oğuz Kaan Köksal
ŞBŞahin Kaan Baydemir
Şahin Kaan Baydemir
HÖHande Nur Nur Öncü
Hande Nur Nur Öncü
FBFatma Ecem Bakan
Fatma Ecem Bakan
NÖNeslihan Öztürk
Neslihan Öztürk
VKVakkas Korkmaz
Vakkas Korkmaz

27 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
HÖHande Nur Nur Öncü
Hande Nur Nur Öncü
GEGökçen Ege
Gökçen Ege
NÖNeslihan öztürk
Neslihan öztürk
OKOğuz Kaan Köksal
Oğuz Kaan Köksal
ŞBŞahin Kaan Baydemir
Şahin Kaan Baydemir
VKVakkas Korkmaz
Vakkas Korkmaz
Aim: To evaluate the diagnostic performance of preoperative computed tomography (CT) using a short-axis diameter threshold of ≥10 mm for predicting lymph node metastasis (LNM) in patients with endometrial cancer.Material and Methods: This retrospective single-center study included 408 patients with endometrial cancer who underwent primary surgical treatment with sentinel lymph node (SLN) mapping and/or systematic lymphadenectomy. Preoperative contrast-enhanced CT scans were reviewed, and lymph nodes with a short-axis diameter ≥10 mm were considered positive. Pathological LNM was defined as metastatic involvement in SLN and/or lymphadenectomy specimens. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and odds ratios (ORs) were calculated.Results: Pathological LNM was identified in 36 patients (8.8%). CT detected lymph node enlargement (≥10 mm) in 39 patients. The sensitivity and specificity of CT for detecting LNM were 50.0% and 94.4%, respectively. PPV was 46.2%, NPV was 95.1%, and overall diagnostic accuracy was 90.5%. CT positivity was significantly associated with pathological LNM (OR 16.7, 95% CI: 8.1–34.3, p < 0.001). However, 18 patients with LNM (50%) had no radiologically enlarged lymph nodes on CT. In multivariable analysis, CT positivity remained independently associated with LNM after adjustment for LVSI and histological type (adjusted OR: 2.83, 95% CI: 1.10–7.29, p = 0.031).Conclusion: Preoperative CT using a ≥10 mm short-axis criterion demonstrates high specificity and negative predictive value but limited sensitivity for detecting lymph node metastasis in endometrial cancer. While CT positivity markedly increases the likelihood of nodal metastasis, a negative CT does not reliably exclude microscopic disease. Therefore, surgical nodal assessment strategies should not rely solely on CT findings.

1 January 2026 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
GEGökçen Ege
Gökçen Ege
HÖHande Nur Nur Öncü
Hande Nur Nur Öncü
NÖNeslihan öztürk
Neslihan öztürk
OKOğuz Kaan Köksal
Oğuz Kaan Köksal
CHCandost Hanedan
Candost Hanedan
VKVakkas Korkmaz
Vakkas Korkmaz
SUMMARY OBJECTIVE: The Hemoglobin–Albumin–Lymphocyte–Platelet score has shown prognostic value across various cancers; however, its utility in predicting cytoreductive outcomes in advanced epithelial ovarian cancer remains unclear. The aim of this study was to determine whether the preoperative Hemoglobin–Albumin–Lymphocyte–Platelet score predicts maximal cytoreduction at primary cytoreductive surgery. METHODS: In this single-center study, we analyzed data from 140 patients with epithelial ovarian cancer who underwent primary cytoreductive surgery at our clinic. Patients were categorized by residual disease: maximal cytoreduction (no macroscopic residual disease, n=104), optimal cytoreduction (n=19), and suboptimal cytoreduction (n=17). Preoperative Hemoglobin–Albumin–Lymphocyte–Platelet, CA-125, and clinical variables were compared across groups. Discrimination for maximal cytoreduction was assessed using receiver operating characteristic analysis. RESULTS: The maximal cytoreduction group had higher preoperative hemoglobin and lymphocyte counts, lower platelet counts, and lower CA-125 levels (p<0.005). Median Hemoglobin–Albumin–Lymphocyte–Platelet was significantly higher in maximal cytoreduction vs. optimal cytoreduction vs. suboptimal cytoreduction (35.37 vs. 21.10 vs. 20.19; all p<0.001). For predicting maximal cytoreduction, the Hemoglobin–Albumin–Lymphocyte–Platelet cutoff of 24.96 yielded a sensitivity of 71.4% and a specificity of 71.4% (area under the curve: 0.792; p<0.001). A CA-125 cutoff of 260.50 IU/mL provided a sensitivity of 71.4% and a specificity of 65.7% (area under the curve: 0.758; p<0.001). CONCLUSION: The preoperative Hemoglobin–Albumin–Lymphocyte–Platelet score demonstrates good discrimination for predicting maximal cytoreduction in advanced epithelial ovarian cancer and appears to perform at least comparably to CA-125. Given that patients selected for neoadjuvant chemotherapy were excluded, these performance estimates apply to a surgically selected population. Given its low cost and universal availability, Hemoglobin–Albumin–Lymphocyte–Platelet may support preoperative selection and counseling before cytoreductive surgery.

21 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CHCandost Hanedan
Candost Hanedan
AİAYŞE NUR İNAL
AYŞE NUR İNAL
AYAyşe Yiğit
Ayşe Yiğit
OKOğuz Kaan Köksal
Oğuz Kaan Köksal
ŞBŞahin Kaan Baydemir
Şahin Kaan Baydemir
CSCaganay Soysal
Caganay Soysal
Background/Objectives: Vaginal cuff hematoma is a recognized complication following hysterectomy, with a subset of patients requiring invasive intervention. No reliable bedside biomarker currently exists to identify at admission patients likely to fail conservative management. This study aimed to evaluate the incidence and clinical characteristics of symptomatic vaginal cuff hematoma across all hysterectomy approaches, and to assess the predictive performance of the CALLY index (CRP-albumin-lymphocyte index), a composite marker of inflammatory burden, immune function, and nutritional status, alongside the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) for identifying patients requiring interventional management. Methods: This retrospective cohort study included 61 patients with symptomatic vaginal cuff hematoma following hysterectomy in a major tertiary referral center (November 2022–July 2025). Patients were divided into conservative (n = 38) and interventional (n = 23) management groups. The CALLY index was calculated as [Albumin (g/dL) × Lymphocyte (×109/L)] ÷ [CRP (mg/L) × 10−2]. Receiver operating characteristic (ROC) curve analysis with the DeLong method was used to compare predictive performance. Results: The overall incidence of symptomatic vaginal cuff hematoma was 1.9% (73/3852 hysterectomies), with the highest rate following vaginal hysterectomy (3.32%) and the lowest after robotic hysterectomy (0.74%). Interventional management was required in 37.7% of patients. The interventional group had significantly higher CRP (192 vs. 62 mg/L, p < 0.001), NLR (7.53 vs. 4.17, p < 0.001), and SII (2308 vs. 1207, p < 0.001), and significantly lower CALLY index values (2.00 vs. 9.80, p < 0.001). The CALLY index demonstrated the highest predictive performance (AUC = 0.863, 95% CI: 0.762–0.964), outperforming SII (AUC = 0.801), NLR (AUC = 0.789), and PLR (AUC = 0.654). At the optimal cutoff of ≤2.89, the CALLY index yielded a sensitivity of 65.2% and a specificity of 92.1%. Conclusions: The CALLY index is a simple, routinely available composite biomarker that may help identify patients at higher risk for interventional management in symptomatic vaginal cuff hematoma. Its incorporation into postoperative assessment may improve risk stratification and support timely clinical decision-making.